Icon

POTASSIUM CHLORIDE (nda019439)- (10MEQ,20MEQ)

POTASSIUM CHLORIDE SCHERING
10MEQ,20MEQ
No No
2006-Sep-05 Expired
None None
None No
POTASSIUM CHLORIDE is indicated for: 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, eg, digitalized patients or patients with significant cardiac arrhythmias.
14 0 12
Total Other Developers None
Drugs with Suitability No
10MEQ ** ** - - 7
20MEQ ** ** - - 7
NDA Sales Available Total Generic Sales Available
No 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ***** **** ******-***** ************, *** *********** ***** **** *** *, ********, ********* (**) *****-****, ****** ****** (***) ***
****** ****** ***** **** ******-***** ************, *** *********** **** ******** ***** *, ***** *****, ********* (**) *****-****, ****** ****** (***) ***
****** ******* **** ** *** ******* ************ **, ***. *********** **** ****** *****, *****, ******* (**) *****, ****** ****** (***) ***
****** ***** ****** *** ***** ***************, ***. *********** *** ****** **., ********, **** (**) *****-****, ****** ****** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** ** *-*, ******* ********** ******, *******-******,, ***, ** ******, ***** (***) ***
****** ***** **** *** ***** ************, ***. *********** *** ****** *****, ********, *** ****** (**) *****, ****** ****** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ****** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** ******** ******** ***** ******* *********** **.**. ***/*, ***/*, ***, ***/*, ********** *******, ********-************* ******, *******-********** ********, ********* ******, ***** (***) ***
****** ******* ******* ******** ******* ******* *********** **** ** *-**/* & ***/*, ****, ********** ********* ****,, *****, *********** *** ***, ***** (***) ***
****** ******** ****** *** ****** ********* *** *** *********** *-* ******** *****, ****** ********** ******, **** ********, ***** *********** *** ***, ****** ******* (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.